A

mid widespread confusion over when the HIV prevention pill will go generic, a spokeswoman for Teva on Monday told STAT that the company has reached a confidential settlement controlling when it can enter the marketplace.

That spokeswoman, Elizabeth DeLuca, declined to say when Teva will launch its generic version of the drug currently sold by Gilead as Truvada, or how much it will charge.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.